ADAM9

ADAM9 詳細

英語名Disintegrin and metalloproteinase domain-containing protein 9市販薬剤の数0
治験薬の数3ターゲットの別称Meltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
研究&開発段階Phase 2 Clinical
英語名Disintegrin and metalloproteinase domain-containing protein 9
ターゲットの別称Meltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
市販薬剤の数0
治験薬の数3
研究&開発段階Phase 2 Clinical

ADAM9バックグランド

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

ADAM9分子の別称

Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein,Meltrin-gamma,Metalloprotease,disintegrin,cysteine-rich protein 9,Myeloma cell metalloproteinase,ADAM9,KIAA0021, MCMP, MDC9, MLTNG

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Izeltabart tapatansineIMGC-936Phase 2 ClinicalImmunogen IncSolid tumours
詳細
DB-1317DB-1317Phase 1 ClinicalDuality Biologics (Suzhou) Co LtdNeoplasm Metastasis; Solid tumours
詳細
MGC-028MGC028; MGC-028Phase 1 ClinicalMacrogenics IncCarcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours
詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8